메뉴 건너뛰기




Volumn 21, Issue 5, 2011, Pages 667-674

How to manage hypersensitivity reactions to biological agents?

Author keywords

Biological agents; Cutaneous adverse drug reactions; Infusion reaction

Indexed keywords

ADALIMUMAB; ADRENALIN; ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; BEVACIZUMAB; BIOLOGICAL PRODUCT; CETUXIMAB; CORTICOSTEROID; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETANERCEPT; ETRETIN; IMATINIB; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; INTERFERON; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; PANITUMUMAB; PLACEBO; PREDNISONE; RITUXIMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

EID: 80054906829     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1468     Document Type: Article
Times cited : (28)

References (50)
  • 1
    • 33745786806 scopus 로고    scopus 로고
    • Adverse side-effects to biological agents
    • Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912-920.
    • (2006) Allergy , vol.61 , pp. 912-920
    • Pichler, W.J.1
  • 2
    • 35548983383 scopus 로고    scopus 로고
    • Management and preparedness for infusion and hypersensitivity reactions
    • Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. The oncologist 2007; 12: 601-9.
    • (2007) The Oncologist , vol.12 , pp. 601-609
    • Lenz, H.J.1
  • 3
    • 77950433553 scopus 로고    scopus 로고
    • Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
    • Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
    • (2010) Allergy , vol.65 , pp. 657-661
    • Vultaggio, A.1    Matucci, A.2    Nencini, F.3
  • 4
    • 70350346904 scopus 로고    scopus 로고
    • Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: A cohort study of 92 patients
    • Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 2009; 219: 263-7.
    • (2009) Dermatology , vol.219 , pp. 263-267
    • Esmailzadeh, A.1    Yousefi, P.2    Farhi, D.3
  • 5
    • 74149087430 scopus 로고    scopus 로고
    • Evénements cutanéomuqueux au cours des traitements par anti-TNF alpha: Étude observationnelle propspective de 41 cas
    • Bonnet N, Guis S, Koeppel MC, et al. Evénements cutanéomuqueux au cours des traitements par anti-TNF alpha: étude observationnelle propspective de 41 cas. Ann Dermatol Venereol 2010; 137: 12-20.
    • (2010) Ann Dermatol Venereol , vol.137 , pp. 12-20
    • Bonnet, N.1    Guis, S.2    Koeppel, M.C.3
  • 6
    • 56549098599 scopus 로고    scopus 로고
    • Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: A cross-sectional study
    • Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 1471-7.
    • (2008) J Eur Acad Dermatol Venereol , vol.22 , pp. 1471-1477
    • Davaine, A.C.1    Saraux, A.2    Prigent, S.3
  • 7
    • 33846950349 scopus 로고    scopus 로고
    • Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists
    • Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
    • (2007) Br J Dermatol , vol.156 , pp. 486-491
    • Lee, H.H.1    Song, I.H.2    Friedrich, M.3
  • 9
    • 0037709396 scopus 로고    scopus 로고
    • Atopic dermatitis-like eruption precipitated by infliximab
    • Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-1.
    • (2003) J Am Acad Dermatol , vol.49 , pp. 160-161
    • Wright, R.C.1
  • 10
    • 0033830347 scopus 로고    scopus 로고
    • Reduced incidence and prevalence of atopy in rheumatoid arthritis
    • Results of a case-control study
    • Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ. Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. Rheumatology (Oxford) 2000; 39: 1020-26.
    • (2000) Rheumatology (Oxford) , vol.39 , pp. 1020-1026
    • Hilliquin, P.1    Allanore, Y.2    Coste, J.3    Renoux, M.4    Kahan, A.5    Menkes, C.J.6
  • 11
    • 2342538439 scopus 로고    scopus 로고
    • Infliximab infusion reactions: Desensitizing ourselves to the danger
    • Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis 2004; 10: 62-3.
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 62-63
    • Persley, K.M.1
  • 12
    • 0038649858 scopus 로고    scopus 로고
    • The incidence and management of infusion reactions to infliximab: A large center experience
    • Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
    • (2003) Am J Gastroenterol , vol.98 , pp. 1315-1324
    • Cheifetz, A.1    Smedley, M.2    Martin, S.3
  • 15
    • 2542637077 scopus 로고    scopus 로고
    • Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab - report of a case
    • Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepato 2004; 16: 627-30.
    • (2004) Eur J Gastroenterol Hepato , vol.16 , pp. 627-630
    • Stallmach, A.1    Giese, T.2    Schmidt, C.3    Meuer, S.C.4    Zeuzem, S.S.5
  • 16
    • 0035007087 scopus 로고    scopus 로고
    • Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction
    • Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7.
    • (2001) Inflamm Bowel Dis , vol.7 , pp. 34-37
    • Puchner, T.C.1    Kugathasan, S.2    Kelly, K.J.3    Binion, D.G.4
  • 17
    • 0036715313 scopus 로고    scopus 로고
    • Cutaneous drug. eruption to infliximab: Report of 4 cases with an interface dermatitis pattern
    • Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug. eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-9.
    • (2002) Arch Dermatol , vol.138 , pp. 1258-1259
    • Vergara, G.1    Silvestre, J.F.2    Betlloch, I.3    Vela, P.4    Albares, M.P.5    Pascual, J.C.6
  • 18
    • 37349003068 scopus 로고    scopus 로고
    • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    • Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 106-115
    • Menter, A.1    Tyring, S.K.2    Gordon, K.3
  • 19
    • 36649025481 scopus 로고    scopus 로고
    • Injection site reactions to TNF-alpha blocking agents with positive skin tests
    • Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008; 63: 138-9.
    • (2008) Allergy , vol.63 , pp. 138-139
    • Benucci, M.1    Manfredi, M.2    Demoly, P.3    Campi, P.4
  • 20
    • 58149117582 scopus 로고    scopus 로고
    • A desensitization protocol for the mAb cetuximab
    • Jerath MR, Kwan M, Kannarkat M, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 2009; 123: 260-2.
    • (2009) J Allergy Clin Immunol , vol.123 , pp. 260-262
    • Jerath, M.R.1    Kwan, M.2    Kannarkat, M.3
  • 21
    • 63949087636 scopus 로고    scopus 로고
    • Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: Report of three cases and review of literature
    • Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 2009; 63: 1017-22.
    • (2009) Cancer Chemother Pharmacol , vol.63 , pp. 1017-1022
    • Saif, M.W.1    Peccerillo, J.2    Potter, V.3
  • 22
    • 54349110930 scopus 로고    scopus 로고
    • Management of severe infusion reactions after cetuximab
    • Cerman J, Melichar B, Cermanova M, Solichova D. Management of severe infusion reactions after cetuximab. Acta Oncol 2008; 47: 1609-11.
    • (2008) Acta Oncol , vol.47 , pp. 1609-1611
    • Cerman, J.1    Melichar, B.2    Cermanova, M.3    Solichova, D.4
  • 23
    • 33846148701 scopus 로고    scopus 로고
    • For TARGET stu dy gro up. Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al.; For TARGET stu dy gro up. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356: 125-34.
    • (2007) N Eng J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 24
    • 47849105015 scopus 로고    scopus 로고
    • Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    • Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-92.
    • (2008) Arch Dermatol , vol.144 , pp. 886-892
    • Autier, J.1    Escudier, B.2    Wechsler, J.3    Spatz, A.4    Robert, C.5
  • 27
    • 0344556916 scopus 로고    scopus 로고
    • Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
    • Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-6.
    • (2003) J Am Acad Dermatol , vol.48 , pp. 201-206
    • Valeyrie, L.1    Bastuji-Garin, S.2    Revuz, J.3
  • 28
    • 20844441783 scopus 로고    scopus 로고
    • Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)
    • Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 2004; 18: 760-2.
    • (2004) Eye , vol.18 , pp. 760-762
    • Esmaeli, B.1    Diba, R.2    Ahmadi, M.A.3
  • 29
    • 0842305855 scopus 로고    scopus 로고
    • Oedème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase: Glivec®
    • Maalouf T, Angioï K, Champigneulle J, Guerci A, George JL. OEdème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase: Glivec®. J Fr Ophtalmol 2004; 27: 107-9.
    • (2004) J Fr Ophtalmol , vol.27 , pp. 107-109
    • Maalouf, T.1    Angioï, K.2    Champigneulle, J.3    Guerci, A.4    George, J.L.5
  • 30
    • 0036816328 scopus 로고    scopus 로고
    • Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia
    • Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69: 254-6.
    • (2002) Eur J Haematol , vol.69 , pp. 254-256
    • Schwarz, M.1    Kreuzer, K.A.2    Baskaynak, G.3    Dörken, B.4    le Coutre, P.5
  • 31
    • 0034837552 scopus 로고    scopus 로고
    • Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
    • Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001; 203: 57-9.
    • (2001) Dermatology , vol.203 , pp. 57-59
    • Brouard, M.C.1    Prins, C.2    Mach-Pascual, S.3    Saurat, J.H.4
  • 33
    • 33748745838 scopus 로고    scopus 로고
    • DRESS (Drug reaction with eosinophilia and systemic symptoms) après traitement par imatinib (Glivec®)
    • Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP, Lok C. DRESS (Drug reaction with eosinophilia and systemic symptoms) après traitement par imatinib (Glivec®). Ann Dermatol Venereol 2006; 133: 686-8.
    • (2006) Ann Dermatol Venereol , vol.133 , pp. 686-688
    • le Nouail, P.1    Viseux, V.2    Chaby, G.3    Billet, A.4    Denoeux, J.P.5    Lok, C.6
  • 35
    • 0036110317 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome after treatment with STI571: A case report
    • Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117: 620-2.
    • (2002) Br J Haematol , vol.117 , pp. 620-622
    • Hsiao, L.T.1    Chung, H.M.2    Lin, J.T.3
  • 36
    • 0037838406 scopus 로고    scopus 로고
    • Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation
    • Schaich M, Schäkel K, Illmer T, Ehninger G, Bornhäuser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003; 82: 303-4.
    • (2003) Ann Hematol , vol.82 , pp. 303-304
    • Schaich, M.1    Schäkel, K.2    Illmer, T.3    Ehninger, G.4    Bornhäuser, M.5
  • 37
    • 14644427729 scopus 로고    scopus 로고
    • Cutaneous reactions to imatinib mesylate treated by topical steroid
    • Ujiie H, Shimizu T, Shimizu H. Cutaneous reactions to imatinib mesylate treated by topical steroid. Am J Hematol 2005; 78: 246.
    • (2005) Am J Hematol , vol.78 , pp. 246
    • Ujiie, H.1    Shimizu, T.2    Shimizu, H.3
  • 39
    • 33646562211 scopus 로고    scopus 로고
    • Imatinib-associated lichenoid eruption: Acitretin treatment allows maintained antineoplastic effect
    • Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006; 154: 1213-6.
    • (2006) Br J Dermatol , vol.154 , pp. 1213-1216
    • Dalmau, J.1    Peramiquel, L.2    Puig, L.3    Fernández-Figueras, M.T.4    Roé, E.5    Alomar, A.6
  • 41
    • 33846657588 scopus 로고    scopus 로고
    • Unique aspects of supportive care using monoclonal antibodies in cancer treatment
    • Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003; 1: 38-48.
    • (2003) Support Cancer Ther , vol.1 , pp. 38-48
    • Dillman, R.O.1    Hendrix, C.S.2
  • 42
    • 50649085243 scopus 로고    scopus 로고
    • Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
    • Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-80.
    • (2008) J Allergy Clin Immunol , vol.122 , pp. 574-580
    • Castells, M.C.1    Tennant, N.M.2    Sloane, D.E.3
  • 43
    • 63249135067 scopus 로고    scopus 로고
    • Plasmapheresis therapy for rare but potentially fatal reaction to rituximab
    • Hastings D, Patel B, Torloni AS, et al. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. J Clin Apher 2009; 24: 28-31.
    • (2009) J Clin Apher , vol.24 , pp. 28-31
    • Hastings, D.1    Patel, B.2    Torloni, A.S.3
  • 44
    • 43149093805 scopus 로고    scopus 로고
    • Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis
    • Serarslan G, Okuyucu E, Melek I, Hakverdi S, Duman T. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. Mult Scler. 2008; 14: 259-61.
    • (2008) Mult Scler , vol.14 , pp. 259-261
    • Serarslan, G.1    Okuyucu, E.2    Melek, I.3    Hakverdi, S.4    Duman, T.5
  • 45
    • 84856537359 scopus 로고    scopus 로고
    • Evaluation d'une pratique de prise en charge des toxidermies dues a l'interferon: A propos de 15 cas
    • Poreaux C, Waton J, Cuny JF, et al. Evaluation d'une pratique de prise en charge des toxidermies dues a l'interferon: a propos de 15 cas. Ann Dermatol Vénéréol 2009; 136: s317-8.
    • (2009) Ann Dermatol Vénéréol , vol.136
    • Poreaux, C.1    Waton, J.2    Cuny, J.F.3
  • 46
    • 84856526170 scopus 로고    scopus 로고
    • Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses
    • In: Bessis D, Francès C, Guillot B, Guilhou JJ, eds, Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique. Springer- Verlag France
    • Bessis D, Dereure O, Guillot B. Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses. In: Bessis D, Francès C, Guillot B, Guilhou JJ, eds, Dermatologie et Médecine, vol.3: Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique. Springer- Verlag France, 2007: 72.1-72.18.
    • (2007) Dermatologie Et Médecine , vol.3
    • Bessis, D.1    Dereure, O.2    Guillot, B.3
  • 47
    • 73349096020 scopus 로고    scopus 로고
    • Omalizumabassociated anaphylactic reactions reported between January 2007 and June 2008
    • Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumabassociated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009; 103: 442-5.
    • (2009) Ann Allergy Asthma Immunol , vol.103 , pp. 442-445
    • Lin, R.Y.1    Rodriguez-Baez, G.2    Bhargave, G.A.3
  • 49
    • 43549089971 scopus 로고    scopus 로고
    • Allergic and nonallergic delayed infusion reactions during natalizumab therapy
    • Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-8.
    • (2008) Arch Neurol , vol.65 , pp. 656-658
    • Hellwig, K.1    Schimrigk, S.2    Fischer, M.3
  • 50
    • 34548602366 scopus 로고    scopus 로고
    • Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies
    • Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-3.
    • (2007) Arch Neurol , vol.64 , pp. 1331-1333
    • Krumbholz, M.1    Pellkofer, H.2    Gold, R.3    Hoffmann, L.A.4    Hohlfeld, R.5    Kümpfel, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.